Did you know that prostate cancer is one of the most prevalent cancers among male Service Members, retirees, and beneficiaries within the Military Health System?
Early detection saves lives. Ask your provider whether miR Sentinel™ is appropriate for your individual situation.
Veterans face a meaningfully elevated risk of prostate cancer compared with the general population.³ Approximately 16,000 veterans receive a prostate cancer diagnosis each year, making it the most commonly diagnosed cancer in the veteran community.²
Suspected causes are well documented: Agent Orange, burn pits, contaminated water, depleted uranium, proximity to EM radiation sources, and other toxic exposures that can come with military service. A review of Vietnam War veterans found that those exposed to dioxin developed prostate cancer at double the rate of unexposed peers, and their tumors were more aggressive.⁴ ⁵
The Department of Defense's 2024 Phase 1B Aviator Cancer Study found that military aircrew had a 15% higher rate of cancer for all sites combined, including a 20% higher rate of prostate cancer, compared to a demographically similar U.S. population.⁷
When prostate cancer is detected at a localized stage, the 5-year relative survival rate is approximately 100%.⁶ Most men diagnosed at a localized stage go on to live full lives.
When the disease is detected late or not at all, the picture changes. The 5-year relative survival rate for distant-stage prostate cancer drops to approximately 37%.⁶
The non-invasive miR Sentinel urine test can support identification of clinically significant prostate cancer when ordered by a healthcare provider for a patient with clinical suspicion of disease — early, accurately, and without relying on PSA alone.
The ACES Act (Signed August 2025)
The Aviator Cancer Examination Study Act directs the U.S. Department of Veterans Affairs and the National Academies of Sciences, Engineering, and Medicine to study cancer rates among veteran fixed-wing aviators. A Department of Defense analysis found that military aircrew face elevated rates of cancer compared with the general U.S. population, with prostate cancer and melanoma showing notable increases.⁷ The ACES Act was signed into law in August 2025 after passing both chambers of Congress with bipartisan support.
The ROTOR Act (Introduced 2025)
The Rotary-wing Operator Toxic Occupational Research Act (H.R. 4704) would extend cancer research to helicopter and tiltrotor crews — a population not covered by the ACES Act. If enacted, the Defense Health Agency, the National Institutes of Health, and the National Cancer Institute would study cancer prevalence among rotary-wing personnel, investigating exposures to fuels, electromagnetic fields, and radar unique to rotary-wing operations.
These laws reflect a growing recognition that military service carries real, long-term cancer risk, and that veterans deserve answers and early-detection tools to match.
Available by prescription only.
Book an appointment with your medical provider and ask whether the miR Sentinel™ Prostate Cancer Test is appropriate for your situation, based on your clinical history and risk factors.
Telemedicine coming soon (Sept. 2026).
Book an appointment with your medical provider and request a prescription for the miR Sentinel™ Prostate Cancer Test.
Download Order Form
A specimen collection kit will be mailed to your home or provider's office.
Follow the instructions included in the collection kit and send your sample to MiRNA Scientific laboratory using the included shipping label.
Your provider will receive a comprehensive results report. Together you will discuss the meaning of the result and next steps.
† FDA Breakthrough Device Designation accelerates the review pathway for novel diagnostics; it does not constitute FDA clearance or approval, and miR Sentinel has not been cleared or approved by the FDA. miR Sentinel is offered as a Laboratory Developed Test (LDT) under CLIA / CAP authority.
1. Wang WW, Sorokin I, Aleksic I, et al. "Expression of small noncoding RNAs in urinary exosomes classifies prostate cancer into indolent and aggressive disease." J Urol. 2020;204(3):466–475. Updated multicenter validation (1,379 patients, NCT04100811 / NCT04661176): manuscript in preparation; performance metrics referenced reflect the pre-specified independent test-set analysis (n=432).
2. US Department of Veterans Affairs. "Prostate Cancer Care at VA." Accessed 20 March 2026. https://www.cancer.va.gov/prostate.html
3. Zhu, Kangmin et al. “Cancer incidence in the U.S. military population: comparison with rates from the SEER program.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 18,6 (2009): 1740-5. doi:10.1158/1055-9965.EPI-09-0041
4. US Department of Veterans Affairs. "Prostate Cancer and Agent Orange." Accessed 20 March 2026. https://www.publichealth.va.gov/exposures/agentorange/conditions/prostate_cancer.asp
5. Ansbaugh, Nathan et al. “Agent Orange as a risk factor for high-grade prostate cancer.” Cancer vol. 119,13 (2013): 2399-404. doi:10.1002/cncr.27941
6. American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026. Available at https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html
7. U.S. Department of Defense. Study on the Incidence of Cancer Diagnosis and Mortality Among Military Aviators and Aviation Support Personnel — Phase 1B (May 2024).https://health.mil/Reference-Center/Reports/2024/05/09/Study-on-the-Incidence-of-Cancer-Diagnosis-and-Mortality
The report will be securely delivered to the provider who ordered the test, either via secure fax or secure email.
The miR Sentinel™ Prostate Cancer Test is commercially available in most U.S. states as well as Puerto Rico. The test is not currently available in New York.
miR Sentinel has CPT PLA code 0424U and is listed on the 2026 Medicare Clinical Laboratory Fee Schedule. Broad coverage policies with private payers remain in build. MiRNA Scientific submits claims and pursues appeals on the patient's behalf. For Medicare beneficiaries: if a Medicare claim is denied, MiRNA Scientific does not bill the patient for any remaining balance. For other patients with out-of-pocket exposure, the miR Access patient-assistance program caps household out-of-pocket cost on a sliding scale based on income, with payment-over-time available. Almost all patients pay no more than approximately $250 for the test.
miR's Sentinel™ Prostate Cancer Test is currently only available through a healthcare provider. Please speak with your physician about possible testing options.
We're here to help! Visit our support center for FAQs and options to connect with a miR Sentinel expert directly.
SUPPORT CENTER
